Actuate Therapeutics provides advanced research for the treatment of high-impact cancers and neurodegenerative diseases.
Actuate Therapeutics is a clinical-stage company developing treatments for hard-to-treat cancers. Its lead drug, elraglusib, targets multiple molecular pathways in cancer, and the company also lists neurodegenerative disease research on Crunchbase.
Actuate Therapeutics was founded in 2015 by Andrew Mazar.
Source: Crunchbase.
Traffic estimates from Semrush, latest month.
Actuate Therapeutics may be growing as indicated by its activities in the biotechnology and pharmaceutical industry. The company has announced its intention to go public with a planned Initial Public Offering (IPO) aiming to raise $50 million, which suggests an expansion of its financial base and potential for increased investment in its research and development efforts. Furthermore, the filing of a registration statement for the IPO and the setting of terms for the public offering are procedural steps that typically precede a company's growth phase associated with becoming a publicly traded entity. Additionally, the announcement of poster presentations at the AACR Annual Meeting demonstrates Actuate Therapeutics' ongoing engagement with the scientific community, which may contribute to its visibility and credibility in the industry.
Source: Crunchbase growth insight.
“Our lead drug, elraglusib, targets multiple molecular pathways in cancer, offering patients the opportunity to live longer and better.” actuatetherapeutics.com
Source: company website, checked 2026-10-26.
Search verified work emails and direct dials for people at actuatetherapeutics.com.
Or explore the full B2B database and filter by biotechnology companies.